Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,056,017 shares, a growth of 28.3% from the December 15th total of 822,858 shares. Currently, 19.9% of the shares of the company are sold short. Based on an average daily volume of 339,735 shares, the short-interest ratio is currently 3.1 days. Based on an average daily volume of 339,735 shares, the short-interest ratio is currently 3.1 days. Currently, 19.9% of the shares of the company are sold short.

Analysts Set New Price Targets

Several analysts have commented on MNPR shares. Piper Sandler set a $95.00 price objective on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research note on Thursday, September 25th. Oppenheimer set a $115.00 target price on shares of Monopar Therapeutics and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. HC Wainwright set a $105.00 price target on Monopar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and an average target price of $107.00.

Insider Activity

In other news, CFO Quan Anh Vu bought 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Monopar Therapeutics

Several large investors have recently made changes to their positions in the company. TCG Crossover Management LLC acquired a new position in shares of Monopar Therapeutics during the 3rd quarter worth approximately $12,496,000. Alyeska Investment Group L.P. acquired a new position in Monopar Therapeutics during the third quarter worth $998,000. Vivo Capital LLC acquired a new position in Monopar Therapeutics during the third quarter worth $7,391,000. Ally Bridge Group NY LLC grew its holdings in Monopar Therapeutics by 86.6% in the 3rd quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock valued at $5,264,000 after buying an additional 29,918 shares in the last quarter. Finally, Deerfield Management Company L.P. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter worth $13,048,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Trading Up 1.3%

MNPR traded up $0.93 during midday trading on Friday, hitting $70.00. 301,279 shares of the company traded hands, compared to its average volume of 313,451. The business has a 50 day simple moving average of $74.62 and a two-hundred day simple moving average of $63.63. Monopar Therapeutics has a 52-week low of $26.06 and a 52-week high of $105.00. The company has a market capitalization of $467.60 million, a price-to-earnings ratio of -20.35 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Equities research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.